230 related articles for article (PubMed ID: 25837660)
1. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.
Lobo JM; Dicker AP; Buerki C; Daviconi E; Karnes RJ; Jenkins RB; Patel N; Den RB; Showalter TN
PLoS One; 2015; 10(3):e0116866. PubMed ID: 25837660
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.
Lobo JM; Trifiletti DM; Sturz VN; Dicker AP; Buerki C; Davicioni E; Cooperberg MR; Karnes RJ; Jenkins RB; Den RB; Showalter TN
Clin Genitourin Cancer; 2017 Jun; 15(3):e299-e309. PubMed ID: 28089723
[TBL] [Abstract][Full Text] [Related]
3. Providing guidance for genomics-based cancer treatment decisions: insights from stakeholder engagement for post-prostatectomy radiation therapy.
Abe J; Lobo JM; Trifiletti DM; Showalter TN
BMC Med Inform Decis Mak; 2017 Aug; 17(1):128. PubMed ID: 28836985
[TBL] [Abstract][Full Text] [Related]
4. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
5. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
6. Reconsidering adjuvant versus salvage radiation therapy for prostate cancer in the genomics era.
Lobo JM; Stukenborg GJ; Trifiletti DM; Patel N; Showalter TN
J Comp Eff Res; 2016 Jul; 5(4):375-82. PubMed ID: 27294829
[TBL] [Abstract][Full Text] [Related]
7. Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study.
Michalopoulos SN; Kella N; Payne R; Yohannes P; Singh A; Hettinger C; Yousefi K; Hornberger J;
Curr Med Res Opin; 2014 Aug; 30(8):1547-56. PubMed ID: 24803160
[TBL] [Abstract][Full Text] [Related]
8. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team.
Fleming C; Wasson JH; Albertsen PC; Barry MJ; Wennberg JE
JAMA; 1993 May; 269(20):2650-8. PubMed ID: 8487449
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
Govers TM; Caba L; Resnick MJ
J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
[TBL] [Abstract][Full Text] [Related]
10. Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.
Parikh R; Sher DJ
Cancer; 2012 Jan; 118(1):258-67. PubMed ID: 21720990
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
12. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
Reed SD; Stewart SB; Scales CD; Moul JW
Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
[TBL] [Abstract][Full Text] [Related]
13. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.
Badani KK; Thompson DJ; Brown G; Holmes D; Kella N; Albala D; Singh A; Buerki C; Davicioni E; Hornberger J
BJU Int; 2015 Mar; 115(3):419-29. PubMed ID: 24784420
[TBL] [Abstract][Full Text] [Related]
14. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ
Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time.
Bhatnagar V; Stewart ST; Bonney WW; Kaplan RM
Urology; 2004 Jan; 63(1):103-9. PubMed ID: 14751359
[TBL] [Abstract][Full Text] [Related]
17. Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting.
Glass AG; Leo MC; Haddad Z; Yousefi K; du Plessis M; Chen C; Choeurng V; Abdollah F; Robbins B; Ra S; Richert-Boe KE; Buerki C; Pearson K; Davicioni E; Weinmann S
J Urol; 2016 Jun; 195(6):1748-53. PubMed ID: 26626216
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
[TBL] [Abstract][Full Text] [Related]
19. Value of information on preference heterogeneity and individualized care.
Basu A; Meltzer D
Med Decis Making; 2007; 27(2):112-27. PubMed ID: 17409362
[TBL] [Abstract][Full Text] [Related]
20. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.
Barocas DA; Alvarez J; Resnick MJ; Koyama T; Hoffman KE; Tyson MD; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF
JAMA; 2017 Mar; 317(11):1126-1140. PubMed ID: 28324093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
